• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Expediting the Discovery and Potential Translation of Theranostic Agents for Alzheimer's Disease

    McClure, Richard Anthony
    : https://etd.library.vanderbilt.edu/etd-08212015-140759
    http://hdl.handle.net/1803/13965
    : 2015-08-21

    Abstract

    Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder characterized by a progressive and inexorable loss of cognitive function most likely attributable to the accumulation of amyloid-β (Aβ) peptide in the brain. Despite this unique molecular etiology, due to the phenotypic homogeneity of neurological disorders included in the differential diagnosis of cognitive impairment, accurately distinguishing AD from non-amyloid-β (Aβ) causes of dementia continues to represent a significant bottleneck in AD research. Notably, the identification of amyloid-binding compounds is a crucial step in the development of imaging probes which can overcome this limitation. Moreover, assuming that amyloid-centric hypotheses are correct, then preventing Aβ plaque formation or facilitating their demolition, particularly during the early disease process, represents a key therapeutic strategy. Disappointingly, the clinical impact of Aβ-binding molecules has been historically stunted due to a systemic underestimation of the impenetrable nature of the blood brain barrier (BBB). Here, with the intent of expanding the chemical genetics of amyloid-binding molecules via the repurposing of hit compounds as theranostic agents for AD, we integrate a novel fluorescence assay with imaging mass spectrometry to screen existing molecular libraries for precursor structures with the ability to both cross the BBB and bind to Aβ-plaques. The therapeutic efficacy of the lead compound identified via this two-phase screening approach, promethazine, was then demonstrated in a preclinical mouse model of AD. In addition, we hypothesized that atomizer technology could be leveraged to enhance the bioavailability of existing disease-modifying therapeutics for AD. In this work, we successfully recapitulated the therapeutic efficacy achieved via intravenous administration of curcumin, but in a dosing regimen compatible with clinical implementation. Together, it is our hope that these scientific contributions will advance the field towards the clinical implementation of the first disease-modifying therapeutic for AD.
    Show full item record

    Files in this item

    Icon
    Name:
    McClure_Richard.pdf
    Size:
    7.172Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy